These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 28689307)

  • 1. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteogenesis Imperfecta Type VI in Individuals from Northern Canada.
    Ward L; Bardai G; Moffatt P; Al-Jallad H; Trejo P; Glorieux FH; Rauch F
    Calcif Tissue Int; 2016 Jun; 98(6):566-72. PubMed ID: 26815784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
    Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
    Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Mutations in SERPINF1 Result in Rare Osteogenesis Imperfecta Type VI.
    Wang JY; Liu Y; Song LJ; Lv F; Xu XJ; San A; Wang J; Yang HM; Yang ZY; Jiang Y; Wang O; Xia WB; Xing XP; Li M
    Calcif Tissue Int; 2017 Jan; 100(1):55-66. PubMed ID: 27796462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
    Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
    Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
    Aström E; Jorulf H; Söderhäll S
    Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X.
    Song Y; Zhao D; Xu X; Lv F; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
    Osteoporos Int; 2018 Jun; 29(6):1389-1396. PubMed ID: 29520608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
    Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
    Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid treatment in children with osteogenesis imperfecta.
    Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
    Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
    Kashii M; Kanayama S; Kitaoka T; Makino T; Kaito T; Iwasaki M; Kubota T; Yamamoto T; Ozono K; Yoshikawa H
    J Bone Miner Metab; 2019 May; 37(3):545-553. PubMed ID: 30187275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
    Feehan AG; Zacharin MR; Lim AS; Simm PJ
    Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment.
    Sato A; Ouellet J; Muneta T; Glorieux FH; Rauch F
    Bone; 2016 May; 86():53-7. PubMed ID: 26927310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.